Drug Metabolism and Pharmacokinetics

Article	Citations
Refined CYP2E1∗ Template∗∗ system to decipher the ligand-interactions	160
Feature importance of machine learning prediction models shows structurally active part and important physicochemical features in drug design	80
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity	43
Protection of mice against carbon tetrachloride-induced acute liver injury by endogenous and exogenous estrogens	41
Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model	21
CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children	21
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality	21
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum	21
Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam	18
Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms	13
Adenosine deaminases acting on RNA modulate the expression of the human pregnane X receptor	12
Functional characterization of human organic anion transporter 10 (OAT10/SLC22A13) as an orotate transporter	12
Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil	11
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis	11
A novel method for predicting the unbound valproic acid concentration	11
Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human	10
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	10
Formation of reactive metabolites of benzbromarone in humanized-liver mice	10
Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development	9
In vitro metabolism of the new antifungal dapaconazole using liver microsomes	9
Identification and characterization of novel metabolites of F2-isoprostanes	8
Potential ADME-related issues for PROTACs	8
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation	8
Assessing victim drug-drug interaction – Reaction phenotyping of CYP and non-CYP	8
Drug induced organ toxicity: Transporter roles and derisking approaches	8

Prediction and validation of human hepatobiliary clearances and hepatic concentrations of transported drugs using the relative expression factor (REF) and PET imaging approaches	7
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy	7
The spectrum of hepatic clearance models, from old to new	7
Modern pediatric drug development: Practical case examples and regulatory outcomes from novel applications of modelling	7
Synthesis and characterization of human metabolites of the echinocandid drug rezafungin by microbial biotransformation	7
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant	7
Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors	7
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib	6
UGT-mediated clearance IVIVE may be improved using relative activity factor approach	6
Metabolism of DHED in vitro and in vivo to support drug optimization	6
Establishment of the relay method for low-turnover compounds in hepatocyte	6
Monocarboxylate transporter 10: substrate-dependent mode of transport	6
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model	6
A practical approach for measuring acyl glucuronide migration half life	6
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human	6
Evaluation of a cost-effective in vitro human model for predicting intrinsic hepatocyte clearance of slowly metabolized compounds	5
Utilizing various plasma protein binding tools for free fraction determination of lipophilic and lipopeptide drugs	5
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies	5
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics	5
Plasma protein binding of oligonucleotides using rapid agarose gel electrophoretic mobility shift assay	5
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption	5
Can LS180 cells predict metabolism and drug-drug interaction potential of UGT2B17 substrates?	5
Redox metabolism in intestine and liver aggravates retronecine-type pyrrolizidine alkaloids-induced liver injury	5
Enriching metabolite fractions for assessment of AHR activation potential: a proof of concept study	5
Dynamic free fraction: concept, methodology and impact on hepatic clearance prediction using the well-stirred model	5
Relative expression versus activity factor (ref vs. raf) to estimate fractional contribution of individual UGT isoforms (FGLUC) in drug glucuronidation	5
Assessment of covalent binding body burden in Hmrel human hepatocyte co-culture model for metabollically low turnover compounds	5
Synthetic mRNA for ex vivo therapeutic applications	4
Validation of LC-MS/MS method for the quantification of buprenorphine and its metabolites in rat’s blood, oral fluid, salivary gland and application the assay on pharmacokinetic study	4
Novel food drug interaction mechanism involving acyclovir, chitosan and endogenous mucus	4
Applications of model simulation in pharmacological fields and the problems of theoretical reliability	4
Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs-	4
Basic tenets for the ADME of protein therapeutics	4
The characterization of the pharmacokinetic profile of anti-tumor B (ATB) in oral cancer patients	4
Latest developments in nitrosamine structure-activity relationships for carcinogenicity	4
Clinical studies on pharmacogenomics and DDIS involving drug transporters	4
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor	4
Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes	4
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	4
Effect of linker-payload design on the PK of ADCS	4
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]	4
Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders	4
Understanding the role of CYP3A in the metabolism of kinase inhibitors marketed in the past decade to better manage the risk of clinical drug-drug interactions	4
Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells	4
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics	4
The refined CYP2B6-Template system for studies of its ligand metabolisms	4
Story of maturation - Modelers vs models in the paediatric space	4
Enzyme induction fundamentals, assays, data interpretation and in vivo translation	4
Evaluation of biliary excretion process of drugs and bile acids using permeation assay by a novel in vitro hepatocyte culture system (ICHEP)	3
From stratified dose adjustment to personalised dosing: Linking LCMS proteomics in tissues to more clinically practical liquid biopsy samples – Opportunities and challenges	3

Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules	3
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene	3
Pharmacokinetic interaction of caffeine and theophylline in mice	3
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human	3
An approach using a gamma-distributed delay model to evaluate the anticancer effect of doxorubicin-encapsulated polymeric micelles by predictive pharmacokinetic-pharmacodynamic modeling	3
An overview of CDE technical guideline for nonclinical study of ADCS: importance and strategy of studying release of payload-containing components from ADC and their further metabolism	3
This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta	3
Hepatocyte formation, reactivity, and stability differences of acyl glucuronide and acyl coenzyme a conjugates	3
One size does not fit all: Preclinical tools to characterize the pharmacokinetics and biodistribution of GaINAc-siRNA	3
In vitro uptake of an MC3 lipid nanoparticle formulation by mice, non-human primate, and human hepatocytes and Kupffer cells	3
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human	3
Physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product	3
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib	3
Cannabinoid-induced drug-drug interactions with hydromorphone.	3
Opportunities and challenges in drug development for retinal diseases	3
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates	3
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions	3
Exploring the human 3D small intestinal model (epiintestinaltm) for improved prediction of oral absorption, metabolism and complex drug-drug interactions of small molecule drugs	3
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition	2
Title page	2
Strategies for enhancing oral exposure of water-insoluble compounds	2
Using quantitative systems pharmacology (QSP) models to characterize the PK of novel drug modalities	2
Deciphering the cell and zonal distribution of drug metabolizing enzymes and transporters in humans by single cell transcriptomics	2
Prediction of human clearance using human liver microsomes and hepatocytes with 455 drugs	2
Gene and oligonucleotide delivery via micro- and nanobubbles by ultrasound exposure	2
Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modeling	2
Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers	2
Plasma protein binding in special populations: do current PBPK models correctly account for potential changes to fraction unbound?	2
Comparison of clearance and metabolic pathways in suspension hepatocytes and hepatopac cultures	2
What is the role of CYP1A1 in drug metabolism?	2
In vivo and in vitro biotransformation of molnupiravir (MOV), An oral prodrug of the antiviral ribonucleoside analog Β-D-N4-hydroxycytidine (NHC)	2
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics	2
Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice	2
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges	2
Novel approaches and troubleshooting for developing a high-throughput oligonucleotide LC-MS method beyond the current stage	2
Novel multi-tissue chips for predictive pharmacokinetic studies	2
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system	2
Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance	2
Gene and Oligonucleotide Delivery	2
Optimization of methods for reducing turnaround time and compound consumptionwith echo liquid handling and automation enabling high capacity analysis for ADME screening	2
Physiologically based pharmacokinetic modeling of CYP2C8 substrate rosiglitazone and its metabolite to predict metabolic drug-drug interaction	1
Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolab	1
Adenovirus vector-based vaccine for infectious diseases	1
Substrate recognition of renally eliminated angiotensin II receptor blockers by organic anion transporter 4	1
Systematic identification and characterization of cynomolgus macaque solute carrier transporters	1
Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice	1
Development of a fluorescent-labeled trapping reagent to evaluate the risk posed by acyl-CoA conjugates	1
Constitutive androstane receptor-responsive elements for mouse Cyp1a2 transcriptional activation induced by constitutive androstane receptor ligands	1
Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model	1
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants	1
Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate	1
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS	1
Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity	1
Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation	1
Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries	1
A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study	1
Quantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers	1
Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings	1
Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations	1
Identification of miRNAs that regulate human CYP2B6 expression	1
Functional role of serine 318 of the proton-coupled folate transporter in methotrexate transport	1
Quantitation and characterization of glucosylsphingosine in cerebrospinal fluid (CSF), plasma, and brain of monkey model with Gaucher disease	1
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	1
Investigating catechin-mediated effects on drug solubility as a mechanism underlying a green tea-raloxifene pharmcokinetic interaction	0
Development of a novel in silico classification model to assess reactive metabolite formation in cysteine trapping assay and investigation of important substructures	0
Development of a high throughput screen for cytochrome P450-ligand binding assays	0
In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450- and transporter-mediated drug-drug interaction	0
Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes	0
Preferential meropenem absorption activated by 1α,25-dihydroxyvitamin D3 and shared with foscarnet, a phosphate transporter substrate, in the rat ileum	0
Determination of metabolic pathways of phosphatidylcholine and lysophosphatidylcholine using a stable isotope tracer in hepatocarcinoma cell lines	0
Is CYP3A4 induction a good indicator for CYP2CS in cryopreserved human hepatocytes?	0
Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients	0
Metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) by Streptomyces griseolus CYP105A1 and its variants	0
In silico approach shows good predictability for free fraction in plasma and volume of distribution in human for drugs subjected to lysosomal trapping	0
Clotrimazole is a potent and selective UGT2B4 chemical inhibitor	0
Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics	0
Phosphate buffer interferes dissolution of prazosin hydrochloride in compendial dissolution testing	0
CYP46A1 inhibition and activation: an in vitro high throughput screening assay to assess possible drug interactions using FDA approved chemical library	0
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in t	0
Validation of a genotyping technique for a surrogate marker of HLA-B58:01 for allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in the Japanese population	0

Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteer	0
Inhibiting uptake activity of organic anion transporter 2 by bile acids	0
Method development to correct tissue concentrations for residual blood: Application to drug distribution in brain tumors	0
Construction of a fused grid-based CYP2C19-Template system and the application	0
Development of a HRMS-MS method for measuring plasma 4Β-hydroxycholesterol, an endogenous biomarker of CYP3A activity, in monkeys treated with CYP3A modulators	0
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: clinical conduct & mass balance	0
Investigation of the learning process of diverse compound structures by chemical language models toward toxicity prediction	0
Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model	0
Identification and characterisation of a novel amino acid conjugate; ergothioneine conjugate of raloxifene through in vitro and in vivo studies	0
Acetaminophen-induced liver injury and the microbiome	0
An in vitro microphysiological model of subcutaneous delivery	0
Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects	0
Update on next generation sequencing of pharmacokinetics-related genes: Development of the PKseq panel, a platform for amplicon sequencing of drug-metabolizing enzyme and drug transporter genes	0
Effect of substrate concentration on reactive metabolite assessment in drug discovery research	0
Preface: In silico technologies to facilitate drug development	0
Increasing the therapeutic index of ADCs with payload binding selectivity enhancers	0
Delivery of small interfering RNAs by nanovesicles for cancer therapy	0
Effects of steric hindrance and electron density of ester prodrugs on controlling the metabolic activation by human carboxylesterase	0
Designing novel RNA medicines for the brain	0
Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity	0
Global expansion of microphysiological systems (MPS) and Japan's initiatives: Innovation in pharmaceutical development and path to regulatory acceptance	0
Practical use of mechanistic modeling to discern real word complex drug interactions	0
Use of human liver microsomes to assess flavin-containing monooxygenase (FMO) metabolism in vitro	0
The mass balance, recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: metabolite characterisation	0
Identification and characterization of erlotinib as a potent mechanism-based inactivator of human aldehyde oxidase	0
Investigating protein-mediated uptake drug-drug interactions using F-methotrexate as a substrate for OATP1B1 transporter	0
Comparison of human biopsy-derived and human iPS cell-derived intestinal organoids established from a single individual	0
Hepatocyte CEBPA restricts the progression of liver fibrosis	0
An overview of selected topics in the clinical pharmacology and translation of in vivo CRISPR-based therapies	0
Establishment of endogenous canine MUC1 knock-out MDCKII cells using CRISPR-Cas9 and evaluation of drug permeation	0
Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration	0
The distribution of perfluorooctanesulfonate (PFOS) into the liver is not dependent on fatty acid binding protein (FABP)	0
LC-MS for identifying changes (or lack of it) in ADME across different cohorts	0
A model-based pharmacokinetic assessment of drug–drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19	0
Food effects on oral drug absorption: Recent advances in understanding mechanisms and quantitative prediction	0
Metabolic pathways of aschantin in human liver preparations	0
Air–liquid interface culture and modified culture medium promote the differentiation of human induced pluripotent stem cells into intestinal epithelial cells	0
Rifampin- and silymarin-mediated pharmcokinetic interactions of pitavastatin, pravastatin, coproporphyrin I, and coproporphyrin III in a transgenic OATP1B mouse model	0
Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology	0
Quantitative estimation of fraction metabolized via CYP3A for low turnover compounds, using hepatocyte co-culture system	0
Challenges associated with the biomarker-informed PBPK modeling of renal transporter-mediated drug interactions	0
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6	0
Systematic investigation of the metabolism of cannabinoids by human cytochrome p450s	0
Method development and optimization for detecting mRNAS of drug metabolizing enzymes and transporters in exosomes derived from human blood	0
Experimental validation of the reliability of dilution method for plasma protein binding assay in human plasma using 12 commercial compounds	0
Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury	0
Strategies for DDI risk assessment between novel oncology agents and combination generic standard of care (SOC) agents	0
Risk of pharmacokinetic drug-drug interactions with novel drugs approved by the US FDA in 2022: a detailed review of DDI data from NDA documentation	0
Novel approach to determine plasma protein binding for labile compounds using equilibrium dialysis	0
Physiological effects of food ingredients on intestinal epithelial cell function	0
Protein-bound uremic toxin clearance as biomarkers of kidney tubular function in diabetic kidney disease	0
Improvement of transdermal absorption rate by nonthermal biocompatible atmospheric pressure plasma	0
Toxicity of trimethoprim and sulfamethoxazole	0
Evaluation of CYP450 activity in HLM bound to magnetizable beads	0
Therapeutic application of sequence-specific binding molecules for novel genome editing tools	0
Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study	0
Metabolism and excretion of therapeutic peptides: current industry practices and recommendations	0
Publisher's note	0
Projections for future challenges and opportunities for pharmacokineticists	0
Exosomes: Breast cancer-derived extracellular vesicles; recent key findings and technologies in disease progression, diagnostics, and cancer targeting	0
Oligonucleotide delivery to antigen presenting cells by using schizophyllan	0
Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats	0
Drug metabolism by the human gut microbiome	0
Liver targeted therapy: What mist and DDI data mean for efficacy	0
Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3)	0
Phenolsulfonphthalein as a surrogate substrate to assess altered function of the prostaglandin transporter SLCO2A1	0
Interactions of sutezolid and its active metabolite with human transporters	0
Clinical DDI trial design and impact on product labels	0
Substrate inhibition potential of arachidonic acid on 14,15-epoxidation, a biological drug developmental target, mediated by recombinant human cytochrome P450 2J2 and 2C8 enzymes	0
Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources	0
In vitro evaluation of metabolism- and transporter-based drug interactions with sunscreen active ingredients	0
Inhibition of cytochrome P450 3A4 enzyme activity by alkaloid psilocin from magic mushrooms: potential for drug interactions	0
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors	0
Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice	0
Translational PK/PD of the targeted radioligand therapy pluvicto	0
Omics analyses and their application for the discovery of biomarkers reflecting drug efficacy and adverse reaction	0
Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin	0
In vitro metabolic stability and in vivo phaarmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors	0
N-nitrosamine safety assessments - Current challenges	0
Novel coc-based liver tissue chip for predictive pharmacokinetic and toxicology applications	0
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase	0
Recent studies on metabolism, DNA adducts, and biomarkers of tobacco carcinogens	0
Pharmacology and translational aspects	0
A synthetic G protein-coupled receptor 40 agonist GW9508 mitigates airway inflammation and mucus secretion in allergic asthma	0
Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions	0
Comparative analysis of microcystin toxicity in 2D and 3D cultured primary human hepatocytes	0
Issues in assessing tissue: Plasma partition coefficients (KP) in PBPK models	0
Development of quantitative translational model of neutropenia using nonclinical animal data and physiological parameters	0
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria	0
Assessing complex drug-drug interactions using the truvivotm hepatocyte model	0
The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects	0
Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions	0
Assessment of the clinical pharmacokinetic interaction potential mediated So-Cheong-Ryong-Tang on a cocktail of anti-inflammatory and anti-biotic drugs, established by physiologically based pharmacoki	0
Evaluation and prediction of oral drug absorption and bioequivalence with food-druginteraction	0
Effect of obesity on pharmacokinetics of transdermal fentanyl: Single-center retrospective study and animal study	0